Epclusa
Phase 3Small molecule
Epclusa is one of 78 small molecule programs targeting Hepatitis. It is currently in Phase 3.
3
Indications
14
Total Trials
3
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
111 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Crestor
AstraZenecaApproved
Repatha
AmgenApproved
Diabeta
PfizerApproved
Neoral
NovartisApproved
Atacand
IIstituto Clinico Humanitas
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Zontivity
Akero TherapeuticsApproved
Propulsid
WWim Janssens
Approved
Zofran
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatitis C3 trials
Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%
Completed·MMacfarlane Burnet Institute for Medical Research and Public Health Ltd·Phase 4·NCT05264558·606 enrolled
Lung Transplantation2 trials
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
Terminated·—·Phase 4·NCT03207399·1 enrolled
Hepatitis C Virus Infection2 trials
Hepatitis1 trial
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
Recruiting·—·Phase 2·NCT03383419·15 enrolled
5 more indications
Acceptability1 trial
Diabetes Mellitus1 trial
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Active, not recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Approved·NCT03520660·121 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epclusa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pennsylvania